stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Shares outstanding
Genmab A/S Sponsored ADR's shares outstanding at the end of fiscal 2025 was $626.9M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $617.1M. Over the past ten years it has ranged from $620.4M (fiscal 2018) to $660.5M (fiscal 2021); the current reading is higher than 30% of that period. Genmab A/S Sponsored ADR ranks 7th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $626.9M | (3.04%) |
| FY2024 | $646.6M | (1.91%) |
| FY2023 | $659.2M | (0.14%) |
| FY2022 | $660.1M | (0.05%) |
| FY2021 | $660.5M | 0.24% |
| FY2020 | $658.9M | 3.53% |
| FY2019 | $636.4M | 2.58% |
| FY2018 | $620.4M | (1.40%) |
| FY2017 | $629.2M | 0.83% |
| FY2016 | $624.0M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $617.1M | (3.36%) |
| Mar 2026 | $638.6M | 1.86% |
| Dec 2025 | $626.9M | 1.00% |
| Sep 2025 | $620.7M | 0.13% |
| 27 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| GMAB Genmab A/S Sponsored ADR | $617.1M |
| RPRX Royalty Pharma PLC compare | $557.0M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| RVMD Revolution Medicines, Inc. compare | $214.9M |
| INCY Incyte Corporation compare | $203.2M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.0M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement